Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study
Table 3
The utilization of different medications between the two groups.
Medication
Group A: stage 2 ()
Group B: stage 3 ()
values1
(%)
(%)
Bisphosphonates
Zoledronic acid
25 (80.6)
28 (96.9)
0.285
Alendronate
6 (19.4)
1 (3.1)
90.0
0.104
Routes
IV
25 (80.6)
28 (96.9)
Oral
6 (19.4)
1 (3.1)
Chemotherapy
Paclitaxel
0
0
3 (7.1)
Cisplatin
5 (27.7)
11 (26.2)
Pemetrexed
6 (33.3)
11 (26.2)
Tegafur/gimeracil/oteracil
2 (11.1)
2 (4.8)
Gemcitabine
0
0
1 (2.4)
25.0
Nedaplatin
1 (5.6)
5
0
0
Cyclophosphamide (IV)
0
0
2 (4.8)
Cyclophosphamide (O)
1 (5.6)
24.0
2 (4.8)
Vindesine
0
0
3 (7.1)
Docetaxel
1 (5.6)
6.0
4 (9.5)
Bortezomib
2 (11.1)
3 (7.1)
2Count
11 (35.4)
21 (72.4)
0.771
Targeted drugs
Apatinib
3 (23.0)
1 (4.5)
15.0
Rituximab (time)
0
0
2 (9.2)
Erlotinib
1 (7.7)
50.0
0
0
Icotinib
3 (23.1)
2 (9.2)
Bevacizumab
1 (7.7)
24.0
2 (9.2)
Gefitinib
3 (23.1)
5 (22.7)
Osimertinib
1 (7.7)
6.0
3 (13.6)
Sunitinib
0
0
3 (13.6)
Anlotinib
0
0
1 (4.5)
3.0
Pazopanib
0
0
1 (4.5)
8.0
Axitinib
0
0
1 (4.5)
5.0
Sorafenib
0
0
1 (4.5)
72.0
Afatinib
1 (7.7)
3.0
0
0
2Count
7 (22.6)
16 (55.2)
0.629
Immunosuppressive drugs
Thalidomide
2 (40.0)
3 (27.2)
GCs
2 (40.0)
NA
7 (63.6)
NA
Anti-PD-1
1 (20.0)
1.0
1 (9.0)
3.0
1 values of medication duration or time were calculated. 2Count: the total number of patients administered with chemotherapy or targeted drugs and the total time or duration of these medications in the two groups were counted. values were statistically significant. The percentage of 2count (%) was the total number of patients receiving chemotherapy or targeted drugs divided by the total number of patients in different groups. SD: standard deviation; NA: not applicable.
